Amgen (AMGN) Announces Significant Data for Repatha in Regressing CAD-Related Atherosclerosis
November 15, 2016 12:46 PM
Amgen (Nasdaq: AMGN) announced that adding Repatha (evolocumab) to optimized statin therapy resulted in statistically significant regression of atherosclerosis in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
